Strides Pharma gets USFDA warning letter for Puducherry facility

The 10 abbreviated new drug applications (ANDAs) pending approval from the Puducherry facility will get deferred till the site is reclassified, Strides Pharma added.

New Delhi: Drug firm Strides Pharma Science Tuesday the US health regulator has issued a warning letter to the company for its Puducherry facility.

The company has now received a warning letter from the United States Food and Drug Administration (USFDA) relating to the Puducherry facility, Strides Pharma Science said in a BSE filing.

The company said its Puducherry site currently produces six products which will not get impacted by the current development.

Also Read: Strides Pharma to sell Australian business for Rs 1900 crore

However, the 10 abbreviated new drug applications (ANDAs) pending approval from the Puducherry facility will get deferred till the site is reclassified, the company added.

Strides said it is committed to the highest standards of quality and compliance, and will work collaboratively with the USFDA to resolve all issues addressed in the warning letter.

The company said it retains its growth guidance for the US market.

Earlier, in May 6, 2019, the company had said that the US health regulator had classified its inspection of the company's Puducherry facility as "Official Action Indicated".

Also Read: Non-compliance of norms: USFDA recommends action against Strides Pharma Puducherry facility